Vitro Biopharma, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
3200 Cherry Creek Drive South, Suite 410, Denver, CO
State of incorporation
NV
Fiscal year end
October 31
Former names
VITRO DIAGNOSTICS INC (to 10/20/2021)
Latest financial report
10-Q - Q2 2024 - Sep 16, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 28.5 % -69.9%
Quick Ratio 2.18 % -72.4%
Debt-to-equity -242 % -152%
Return On Assets -132 % -89.3%
Operating Margin -481 % -33.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.46M shares +0.68%
Common Stock, Shares, Outstanding 4.46M shares +0.68%
Entity Public Float 0 USD
Common Stock, Value, Issued 4.46K USD +0.68%
Weighted Average Number of Shares Outstanding, Basic 4.46M shares +0.68%
Weighted Average Number of Shares Outstanding, Diluted 4.46M shares +0.68%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 320K USD -44.6%
Revenue from Contract with Customer, Excluding Assessed Tax 1.85M USD +12.3%
Research and Development Expense 522K USD +354%
Operating Income (Loss) -8.91M USD -49.8%
Net Income (Loss) Attributable to Parent -9.76M USD -65.1%
Earnings Per Share, Basic -2.18 USD/shares -7.92%
Earnings Per Share, Diluted -2.18 USD/shares +85%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 181K USD +7094%
Accounts Receivable, after Allowance for Credit Loss, Current 69.1K USD -12.9%
Inventory, Net 215K USD +14.2%
Assets, Current 1.93M USD -41.6%
Property, Plant and Equipment, Net 180K USD -50.1%
Operating Lease, Right-of-Use Asset 378K USD +39.2%
Intangible Assets, Net (Excluding Goodwill) 617K USD -51.7%
Goodwill 3.61M USD 0%
Other Assets, Noncurrent 8.44K USD -50.6%
Assets 6.81M USD -25.4%
Accounts Payable, Current 2.32M USD
Accrued Liabilities, Current 1.6M USD
Liabilities, Current 10.2M USD +149%
Operating Lease, Liability, Noncurrent 256K USD -33.6%
Liabilities 14.1M USD +62%
Retained Earnings (Accumulated Deficit) -35.9M USD -37.1%
Stockholders' Equity Attributable to Parent -7.32M USD -1933%
Liabilities and Equity 6.81M USD -25.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.2M USD -26.4%
Net Cash Provided by (Used in) Financing Activities 2.98M USD +666%
Net Cash Provided by (Used in) Investing Activities -486 USD
Common Stock, Shares Authorized 19.2M shares 0%
Common Stock, Shares, Issued 4.46M shares +0.68%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.54M USD +441%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.89K USD -15.6%
Deferred Tax Assets, Valuation Allowance 5.05M USD +36.2%
Deferred Tax Assets, Gross 5.05M USD +36.2%
Operating Lease, Liability 378K USD +39.2%
Depreciation 175K USD +11.1%
Lessee, Operating Lease, Liability, to be Paid 637K USD -19.9%
Property, Plant and Equipment, Gross 1.06M USD -0.53%
Operating Lease, Liability, Current 122K USD -2.96%
Lessee, Operating Lease, Liability, to be Paid, Year Two 167K USD +1.74%
Lessee, Operating Lease, Liability, to be Paid, Year One 164K USD +1.77%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 259K USD -8.92%
Lessee, Operating Lease, Liability, to be Paid, Year Three 84.6K USD -49.3%
Deferred Tax Assets, Operating Loss Carryforwards 3.07M USD +42.1%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 67.7K USD -19.9%
Operating Lease, Payments 56.9K USD +11.1%
Additional Paid in Capital 28.7M USD +7.48%
Amortization of Intangible Assets 83.8K USD -58.5%
Interest Expense 2.51M USD +1345%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%